Numerous strategies may be needed to control IFIS

Article

Intraoperative floppy iris syndrome (IFIS) can be approached in a number of ways depending on the surgical scenario, according to David Chang, MD, University of California, San Francisco.

Intraoperative floppy iris syndrome (IFIS) can be approached in a number of ways depending on the surgical scenario,according to David Chang, MD, University of California, San Francisco.

"There is great variability in how the iris responds among patients with IFIS," Dr. Chang said. "We have to control it, or itmay or may not work, which is why multiple strategies are needed."

The first approach that he uses, an ophthalmic viscosurgical device (OVD), provides good pupillary dilation in patients whoare taking tamsulosin (Flomax, Boehringer Ingelheim Pharmaceuticals), as Dr. Chang demonstrated in a mild case of IFIS.Gentle hydrodissection, horizontal chopping, and low flow are advised in these cases, he said. The key to using an OVD is toprolong its duration in the eye. He achieves visco mydriasis by refilling the eye with a proprietary OVD, 2.3% sodiumhyaluronate (Healon5, Advanced Medical Optics), as needed. However, he noted, there is a learning curve associated with theuse of this OVD.

Another strategy in patients with IFIS in whom an OVD alone may not work is the use of intracameral epinephrine, whichprovides pupillary rigidity and eliminates any billowing of the iris. In these cases, epinephrine is mixed with balanced saltsolution in a 1:4 ratio. Dr. Chang demonstrated a case in which epinephrine was used, there was no prolapse, and the irisbillowing stopped. In cases of severe IFIS, epinephrine may need more time to work.

When epinephrine is ineffective, Dr. Chang reported that he combines 2.3% sodium hyaluronate and epinephrine to dilate thepupil successfully.

In patients with a small pupil, iris retractors (available from Katena and FCI) may be used when intracameral epinephrine isineffective. Dr. Chang makes a separate stab incision from the phaco incision. The retractor forms the iris in a diamondconfiguration, which eliminates tenting of the iris and provides good exposure nasally for chopping.

The latest strategy is the disposable expansion ring. This device provides a 6-mm pupil diameter. The ring has a low profileallowing for easy access of the instrument to the eye. Dr. Chang said that, in his opinion, he considers one proprietary ring(Malyugin Ring, Microsurgical Technologies) to be among the easiest devices to use.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.